|
| | | | |
|
 | | NOVOZYMES BIOPHARMA ANNOUNCES NEW DEVELOPMENT IN ANIMAL-FREE CELL CULTURE SUPPLEMENTS AT BIOPROCESS INTERNATIONAL CONFERENCE AND EXHIBITION 2008 | | | Novozymes Switzerland AG | | 17/09/2008 | | | Novozymes Biopharma, part of Novozymes, world leader in bioinnovation, announces a new development in animal-free supplements for industrial cell culture on booth #219 at BioProcess International Conference and Exhibition, 23-26 September 2008, Disneyland Hotel, Anaheim, CA, USA.
Novozymes Biopharma, specialists in large scale recombinant protein production for the biopharmaceutical industry, unveils the first product under the CellPrime™ brand. Novozymes’ Transferrin recombinant supplement is now commercially ready in scalable manufacturing quantities for consistency of supply. Designed to reduce risk and ease regulatory concerns for biopharmaceutical manufacturers, this new advance will improve the consistency and productivity of customers’ industrial cell culture process. Manufactured by Novozymes Biopharma, Transferrin is sold exclusively through Millipore Corporation as part of the CellPrime alliance announced in December 2007.
Novozymes Biopharma will also exhibit its two key product lines, Recombumin® and LONG®R3 IGF-I, on booth #219. Recombumin® is a yeast derived recombinant human albumin, which has a structure identical to human serum albumin (HSA). It is the world’s first and only animal-free recombinant human albumin approved for use in the manufacture of human therapeutics. LONG®R3 IGF-I is an analogue of human insulin-like growth factor I (IGF-I) specifically engineered by Novozymes Biopharma for use in industrial cell culture. LONG®R3 IGF-I provides improved performance and a consistent, compliant and animal-free alternative to recombinant insulin.
Novozymes Biopharma’s portfolio includes biopharmaceutical technologies and services, contract manufacturing of pharmaceutical grade biological APIs, and services such as cell banking, technology transfer and process development.
Novozymes Biopharma demonstrates in-depth expertise during the technical conference with:-
• A poster display on “Advances in animal free media supplements for optimal cell culture performance,” presented by Sally Grosvenor, Senior Scientist and Scientific Communications Manager, Novozymes Biopharma AU Ltd. in the poster area, Disneyland Hotel, Anaheim.
• A workshop, entitled “Cell Culture and Processing Track” hosted by Sally Grosvenor, on 25th September 2008 at Magic Kingdom 2 and 3 at 12-12.30pm, will discuss the ability of two key serum proteins, Transferrin and IGF-I, to stimulate cell growth and productivity.
• Geoff Francis, Chief Scientist, Novozymes Biopharma AU Ltd is moderator of the Novozymes sponsored Panel Discussion “Cell Engineering the Future – A Role for Media Innovation” 12.30pm on 25th September 2008. | |
|
| | | View similar articles: | | |
| | | |
|
 | People who viewed this article were also interested in |  | |  |
|
| Other articles from Novozymes Switzerland AG | | | |
|